AbbVie Inc (ABBV)vsPennant Group Inc (PNTG)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
PNTG
Pennant Group Inc
$30.71
-0.26%
HEALTHCARE · Cap: $1.07B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6353% more annual revenue ($61.16B vs $947.71M). ABBV leads profitability with a 6.9% profit margin vs 3.1%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
PNTG
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+73.0%
Fair Value
$117.14
Current Price
$30.71
$86.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 53.2% year-over-year
Earnings expanding 53.7% YoY
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
3.1% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : PNTG
The strongest argument for PNTG centers on Revenue Growth, EPS Growth. Revenue growth of 53.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : PNTG
The primary concerns for PNTG are PEG Ratio, P/E Ratio, Market Cap. Thin 3.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
ABBV profiles as a value stock while PNTG is a hypergrowth play — different risk/reward profiles.
PNTG carries more volatility with a beta of 1.30 — expect wider price swings.
PNTG is growing revenue faster at 53.2% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 59/100). PNTG offers better value entry with a 73.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Pennant Group Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Pennant Group, Inc. provides health care services in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company is headquartered in Eagle, Idaho.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?